Dogwood Therapeutics (DWTX) Accounts Payables (2020 - 2026)

Dogwood Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $411516.0 in Q2 2026.

• On a quarterly basis, Accounts Payables fell 17.39% year-over-year to $411516.0 in Q2 2026; TTM through Jun 2026 was $411516.0, a 17.39% decrease from a year earlier, with the FY2025 full-year figure at $760945.0, down 38.23% from the prior year.
• Accounts Payables was $411516.0 for Q2 2026 at Dogwood Therapeutics, up from $144400.0 in the prior quarter.
• The five-year high for Accounts Payables was $1.2 million in Q4 2024, with the low at $111913.0 in Q4 2023.
• Average Accounts Payables over 5 years is $476111.1, with a median of $433239.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Accounts Payables soared 1000.68% in 2024, then sank 87.48% in 2026.
• Over 5 years, Accounts Payables stood at $573164.0 in 2022, then slumped by 80.47% to $111913.0 in 2023, then jumped by 1000.68% to $1.2 million in 2024, then slumped by 38.23% to $760945.0 in 2025, then plunged by 45.92% to $411516.0 in 2026.
• The last three Accounts Payables figures came in at $411516.0 (Q2 2026), $144400.0 (Q1 2026), and $760945.0 (Q4 2025), per Business Quant data.